Team

Rescue Hearing’s initial gene therapy product will target a genetic mutation known to cause progressive hearing loss which eventually leads to deafness.

DR. HINRICH STAECKER

MD, PHD

RHI Chief Scientific Advisor
University of Kansas Medical Center. Created the first and only gene therapy for hearing loss approved for human clinical trials (Novartis CGF166).

DR. ZHENG-YI CHEN

D. PHIL

RHI Scientific Advisor
Mass Eye and Ear Infirmary Harvard Medical School. Dr. Chen’s lab was responsible for generating RHI100’s groundbreaking POC data.

DR. XUE ZHONG LIU

Manager

RHI Scientific Advisor hysician Surgeon University of Miami. Expertise in identifying the genetic causes of hearing loss one of the top NIH funded Otolaryngologists.

DR. JEFFREY HOLT

SCIENTIFIC ADVISORY BOARD

RHI Scientific Advisor Boston Children’s Hospital Harvard Medical School. Expertise in developing vector constructs for the delivery of gene therapies to the inner ear.

DR. LEE GOLDEN

SCIENTIFIC ADVISORY BOARD

MD Clinical Trial Design Drug Development. 19 years in experience in all phases of drug development. Currently the Head of Global Clinical Development at PTC Therapeutics

ANDREW KOOPMAN

SCIENTIFIC ADVISORY BOARD

Investor Relations Business Development More than 30 years in Biotechnology and Biomedical industries.

Dr. Athanasia Warnecke

SCIENTIFIC ADVISORY BOARD

Hannover Medical School. Expertise in presenting human clinical trial briefing
packages to the Paul-Ehrlich-Institute (PEI).